603392 万泰生物
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,948,111-60.79%5,510,78311,185,1895,750,3292,354,257
减:营业总成本1,928,980-37.28%3,878,7175,747,9093,404,1151,587,661
    其中:营业成本548,825-7.24%792,1251,170,412817,711442,142
               财务费用(41,813)-32.77%(92,977)(61,612)5,19511,367
               资产减值损失(10,588)-64.42%(459,733)(20,503)(29,841)(29,155)
公允价值变动收益13,336-21.99%24,6579,97728349
投资收益93,45315.10%98,89836,11311,22513,606
    其中:对联营企业和合营企业的投资收益----------2,247
营业利润264,473-86.81%1,401,4515,596,0382,328,456775,203
利润总额246,152-87.71%1,393,3925,582,6912,324,145764,452
减:所得税费用(24,334)-112.74%146,887719,390244,93182,636
净利润270,486-85.07%1,246,5044,863,3012,079,214681,815
减:非控股权益3,83712.81%(1,175)127,50657,7474,818
股东净利润266,649-85.25%1,247,6804,735,7952,021,468676,997

市场价值指针
每股收益 (元) *0.210-85.31%0.9903.7902.3001.150
每股派息 (元) *----0.3201.0000.2000.250
每股净资产 (元) *9.820-6.42%10.01513.6217.3575.889
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容